See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/223992363

# Piperine, a Component of Black Pepper, Inhibits Adipogenesis by Antagonizing PPARγ Activity in 3T3-L1 Cells

**ARTICLE** *in* JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY · APRIL 2012

Impact Factor: 2.91 · DOI: 10.1021/jf204514a · Source: PubMed

CITATIONS READS
13 117

# 8 AUTHORS, INCLUDING:



Ui-Hyun Park

Sejong University

13 PUBLICATIONS 322 CITATIONS

SEE PROFILE



Taesun Park

Yonsei University

96 PUBLICATIONS 1,357 CITATIONS

SEE PROFILE



Seung Kew Yoon

Catholic University of Korea

247 PUBLICATIONS 3,577 CITATIONS

SEE PROFILE



# Piperine, a Component of Black Pepper, Inhibits Adipogenesis by Antagonizing PPARy Activity in 3T3-L1 Cells

Ui-Hyun Park,<sup>†</sup> Hong-Suk Jeong,<sup>§</sup> Eun-Young Jo,<sup>§</sup> Taesun Park,<sup>#</sup> Seung Kew Yoon,<sup>⊗</sup> Eun-Joo Kim,<sup>⊥</sup> Ji-Cheon Jeong,\*<sup>,§</sup> and Soo-Jong Um\*<sup>,†</sup>

ABSTRACT: This study investigated the antiadipogenic activity of black pepper extract and its constituent piperine in 3T3-L1 preadipocytes as well as the underlying molecular mechanisms. Both black pepper extract and piperine, without affecting cytotoxicity, strongly inhibited the adipocyte differentiation of 3T3-L1 cells. The mRNA expression of the master adipogenic transcription factors, PPARγ, SREBP-1c, and C/EBPβ, was markedly decreased. Intriguingly, mRNA levels of PPARγ target genes were also down-regulated. Moreover, a luciferase reporter assay indicated that pipierine significantly represses the rosiglitazone-induced PPARy transcriptional activity. Finally, GST-pull down assays demonstrated that piperine disrupts the rosiglitazone-dependent interaction between PPARy and coactivator CBP. Genome-wide analysis using microarray further supports the role of piperine in regulating genes associated with lipid metabolism. Overall, these results suggest that piperine, a major component of black pepper, attenuates fat cell differentiation by down-regulating PPARy activity as well as suppressing PPARγ expression, thus leading to potential treatment for obesity-related diseases.

KEYWORDS: Piper nigrum Linne, black pepper, piperine, adipogenesis, adipocytes, peroxisome proliferator-activated receptor-y

#### INTRODUCTION

Obesity is known to be the most prevailing and common health dilemma to be solved throughout the world. However, its complex etiology has been an obstacle for its treatment. In general, obese condition is mainly caused by excess accumulation of lipid and triglycerides in adipose tissue, which plays a pivotal role in energy balance with regulation of lipid homeostasis, glucose uptake in blood, and endocrine function.<sup>2</sup> Under the condition of excess energy, adipose tissues increase the number of adipocytes from preadipocytes by inducing differentiation.<sup>3</sup> Therefore, it is very important to control adipogenesis for regulating energy homeostasis and obesity.

Adipogenesis is a well-organized process regulated by adipogenic transcription factors, such as peroxisome proliferator-activated receptor-γ (PPARγ), sterol regulatory element binding protein (SREBP) family, and CCAAT-enhancer binding protein (C/EBP) family.<sup>4-6</sup> Of these factors, PPARγ has been focused on its role in adipocyte differentiation. In addition to being induced during adipogenesis, it is both necessary and sufficient for the process.7 Once bound to a ligand such as synthetic thiazolidinediones (TZDs), PPARy forms a heterodimer with retinoid X receptor (RXR) and regulates the expression of specific subsets of genes containing a PPAR-response element (PPRE) in their promoters. These genes include fatty acid binding protein 4 (Fabp4 or aP2), adipsin, and lipoprotein lipase (LPL). 7-10 Recently, many other PPARy target genes have been supplemented by genome-wide microarray and ChIP analysis. 11-12

Black pepper is a well-known spice used worldwide for hundreds of years. Piper nigrum Linne (PnL), the source of black pepper, has been traditionally used for cholera, dyspepsia. gastric ailments, and diarrhea as an oriental medicinal plant. 15-17 It also has been reported that PnL reduces triglyceride accumulation in liver and levels of glucose and lipid in the blood. 18,19 Piperine, a pungent ingredient of black pepper, is a major alkaloid-amine component of PnL extract.<sup>20</sup> In addition to many efficacies such as painkiller, <sup>21</sup> antioxidant, <sup>22,23</sup> antitumor, <sup>24,25</sup> and anti-inflammation activities, <sup>26</sup> piperine also plays an important role in reducing the levels of lipids and glucose in the blood, <sup>27,28</sup> and thus decreasing blood pressure.<sup>29</sup> However, the molecular mechanisms underlying the piperine effects remain largely unknown.

In this study, we investigated the role of PnL extract and its component piperine in adipogenesis and adipogenic gene expression using 3T3-L1 preadipocytes. In addition, we explored the molecular mechanism of the piperine effect by focusing on its role in PPARy regulation. Overall, our results

Received: November 8, 2011 March 26, 2012 Revised: Accepted: April 2, 2012 Published: April 2, 2012

<sup>&</sup>lt;sup>†</sup>Department of Bioscience and Biotechnology, BK21 Graduate Program, Sejong University, Seoul 143-747, Korea

<sup>§</sup>Department of Biochemistry, Molecular Biology and Internal Medicine, College of Oriental Medicine, Dongguk University, Kyungpook 780-714, Korea

Department of Food and Nutrition, Brain Korea 21 Project, Yonsei University, Seoul 120-749, Korea

<sup>&</sup>lt;sup>⊗</sup>Department of Internal Medicine, The Catholic University of Korea, Seoul 137-701, Korea

<sup>&</sup>lt;sup>1</sup>Department of Molecular Biology, BK21 Graduate Program, Dankook University, 126 Jukjeon-dong, Suji-gu, Yongin-si, Gyeonggi-do 448-701, Korea

Table 1. Primer Sequences Used for qPCR

gene	forward primer	reverse primer
Pparg	TTTTCAAGGGTGCCAGTTTCAATCC	AATCCTTGGCCCTCTGAGAT
Srebp-1c	CTGAGGCAAAGCTGAATAAATCTGCTG	GTTCTCCTGCTTGAGTTTCTGGTTG
C/EBP	ACGAGCGCCCATCGACTTC	GAAGCCCGGCTCCGCCTTG
adipsin	CCTGAACCCTACAAGCGATG	GGTTCCACTTCTTTGTCCTCG
Lpl	ATCCATGGATGGACGGTAACG	CTGGATCCCAATACTTCGACCA
aP2	AAAGACAGCTCCTCCTCGAAGGTT	TGACCAAATCCCCATTTACGC
Cd36	GTCCTGGCTGTTTTGGAGG	CTTGGCTAGATAACGAACTCTGTA
Glut4	AGGGGCCTGCCCGAAAGAGT	CTGTTGGCTCAGCTGCAGCAC
Lxra	GCTGCCCAGCAACAGTGTAA	CTGCCGGGGTTGTACCTCCGT
Scd1	CATCCCATCGCCTGCTCTACC	GAAACCTGCCCTCCTGACTCTC

suggest that piperine could be a lead natural compound for the treatment of fat-related disorders.

#### ■ MATERIALS AND METHODS

Reagents and Chemicals. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Oil Red O, dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), insulin, dimethyl sulfoxide (DMSO), piperine, rosiglitazone, GW9662, and To901317 were purchased from Sigma (St. Louis, MO, USA). Fetal bovine serum (FBS) and bovine serum (BS) were obtained from GIBCO (Grand Island, NY, USA).

**Extraction of** *P. nigrum* **Linne.** The crushed *P. nigrum* Linne (PnL), supplied by the Oriental Medical Hospital of Dongguk University (Kyungju, Korea), was extracted three times, each time with 3 volumes of methyl alcohol at 60 °C for 24 h. The extract was then cooled to room temperature, filtered, evaporated under a reduced pressure using a rotary evaporator, and dissolved in DMSO.

MTT Assays. 3T3-L1 cells were grown in DMEM supplemented with 10% (v/v) BS and 1% antibiotics/antimyotics (Invitrogen, Carlsbad, CA, USA) and plated at 500 cells/well in a 96-well tissue culture plate. Indicated concentrations of PnL extract and piperine were treated and incubated for 72 h. Fifty microliters of MTT reagent (2 mg/mL) was added and incubated in each well for 4 h. The MTT medium was then replaced with 0.2 mL of DMSO, and absorbance was read at 550 nm.

**Adipocyte Differentiation of 3T3-L1 Cells.** 3T3-L1 cells were grown in DMEM supplemented with 10% (v/v) BS and 1% antibiotics/antimyotics (Invitrogen) at 37 °C and 5% CO $_2$  to confluence. After 2 days, cells were induced to adipocyte differentiation (day 0) with 0.5  $\mu$ M dexamethasone, 100  $\mu$ M IBMX, and 1  $\mu$ g/mL insulin with or without the indicated PnL extract or piperine in DMEM supplemented with 10% FBS. After 2 days, and every 2 days thereafter, cells were switched to fresh medium containing DMEM plus 10% FBS, 1  $\mu$ g/mL insulin, and PnL extract or piperine. After 10 days, cells were harvested for further experiments.

**Oil Red O Staining.** 3T3-L1 cells differentiated for a total of 10 days were washed twice with PBS (pH 7.4) and then fixed with 2 mL of 10% formalin in PBS for 30 min at room temperature. The cells were washed twice with 2 mL of distilled water and stained with 0.5% Oil Red O (Sigma) for 10 min with gentle agitation. Excess stain was removed with 60% isopropanol, and cells were washed twice with distilled water before being photographed under a light microscope. Accumulated lipids were extracted in 2 mL of 100% isopropanol and measured by reading absorbance at OD 500 nm.


RNA Extraction and Real-Time Quantitative RT-PCR. Total RNA was extracted from differentiated 3T3-L1 cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The cDNA was synthesized with 1  $\mu$ g total RNA using MMLV reverse transcriptase and random primers (Invitrogen). Quantitative real-time PCR (qPCR) reactions were performed using the iQ SYBR Green Supermix and Icycler CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA, USA). The thermal cycle conditions were initial denaturation at 95 °C for 3 min, followed by 40 cycles at 95 °C for 15 s, 58 °C for 20 s, and 72 °C for 20 s. Cycle threshold ( $C_1$ ) values were

determined in 20–30 cycles. Primers used for qPCR are shown in Table 1. All expression levels were normalized using GAPDH as an internal standard in each well. Fold expression was defined as the fold increase relative to controls.

Luciferase Reporter Gene Assays. HEK293 cells were seed in a 12-well plate and cotransfected with PPAR $\gamma$ , PPRE-tk-luciferase reporter gene (PPAR $\gamma$  response element fused to thymidine kinase promoter localized upstream of luciferase gene), and SV-40-driven  $\beta$ -galactosidase expression vectors using LipofectAMINE (Invitrogen). After transfection overnight, cells were fed DMEM containing 5% charcoal-stripped FBS and incubated overnight in the presence of rosiglitazone (1  $\mu$ M) and increasing concentrations of piperine. Luciferase activity was measured as described previously. <sup>30</sup>

Glutathione S-Transferase (GST) Pull-down Assays. Here, we used the notion that the N-terminal domain of CREB-binding protein (CBP) interacts with the ligand-binding domain of PPAR $\gamma$  only in the presence of its ligand. The CBP-PPAR $\gamma$  interaction was monitored by a GST pull-down assay as previously described with minor modifications.<sup>33</sup> The His (6X)-tagged ligand-binding domain of PPARγ (amino acids 315–505) was purified using a HiTrap Chelating HP column (GE Healthcare, Piscataway, NJ, USA). GST and GSTfused CBP (amino acids 1-460 and 602-1095) were purified on glutathione-Sepharose beads (GE Healthcare). Glutathione-Sepharose beads were equilibrated with binding buffer [50 mM Tris-Cl, pH 7.5, 200 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1 mM phenylmethanesulfonyl fluoride (PMSF), 0.1% Nonidet-40]. Approximately equimolar amounts of GST (0.5  $\mu$ g) or GST-CBP (1  $\mu$ g) were mixed with 0.2  $\mu$ g of His-PPAR $\gamma$  in the binding buffer supplemented with 10 µM rosiglitazone and/or indicated concentrations of piperine, and the mixtures were incubated at 30 °C for 30 min. Pre-equilibrated glutathione-Sepharose beads were added, and further incubation was allowed for 1 h. The beads were washed three times with the binding buffer. Bound proteins were eluted with 40  $\mu L$ of 2× SDS loading buffer by boiling for 10 min and visualized by Western blotting using anti-His antibody (Applied Biological Materials, Richmond, Canada).

Microarray and Data Analysis. Total RNA was extracted from 3T3-L1 cells treated with 50  $\mu g/mL$  PnL extract or 50  $\mu M$  piperine for 10 days under the adipogenesis condition. RNA quantity and quality were checked using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA samples with an RNA integrity number (RIN) of >9 were used for further analysis in a two-color microarray experiment using Agilent-Mouse-44k-4plex according to the manufacturer's instructions. Equal amounts of total RNA were amplified, labeled, hybridized, washed, and scanned. The LOWESS (locally weighted linear regression curve fit) and dye-swap normalization methods were applied to the ratio (Cy5/Cy3) of the signal intensities generated in the microarrays. Results were filtered, and the cutoff was set at increase and decrease of 1.5-fold change. Genes exhibiting differences in expression level were classified into Gene Ontology (GO)-based functional categories (http://www.geneontology.org), KEGG (http://www.genome.jp/kegg/), and DAVID Bioinformatics Resources (http://david.abcc. ncifcrf.gov/).



**Figure 1.** Effect of *Piper nigrum* Linne (PnL) extract and its component piperine on lipid accumulation in 3T3-L1 cells. (A, B) Cytotoxicity of PnL extract and piperine. 3T3-L1 cells were exposed to different concentrations of PnL extract (A) or piperine (B) for 72 h. Cytotoxicity was measured by MTT assays. (C, D) Oil Red O staining and measurement of lipid content. 3T3-L1 cells were differentiated and treated with DMSO, PnL extract (50  $\mu$ g/mL), or piperine (50  $\mu$ M). After differentiation for 10 days, cellular lipid droplets were stained with Oil Red O (upper plates are magnification ×10) (C) or eluted and measured at OD 500 nm (D). Data reflect the mean  $\pm$  SD of three independent experiments. \*, p < 0.05, and \*\*, p < 0.01, compared to DMSO control.

## RESULTS


P. nigrum Linne (PnL) Extract and Piperine Inhibit **Lipid Accumulation in 3T3-L1 Cells.** Prior to determining the effect of PnL extract and its major constituent piperine on the lipid accumulation associated with adipocyte differentiation in 3T3-L1 cells, we determined the cytotoxicity of PnL extract and piperine using MTT assays. As shown in Figure 1, panels A and B, no significant effects of PnL extract and piperine on the proliferation of 3T3-L1 cells were observed for concentrations of 50  $\mu$ g/mL and 200  $\mu$ M, respectively. Subsequent Oil Red O staining indicated that PnL extract (50 µg/mL) and piperine (50 μM) significantly decreased lipid accumulation compared to the DMSO-treated control cells upon differentiation for 10 days (Figure 1C). To quantify the level of lipid accumulation, we extracted lipid from Oil Red O stained cells. The lipid contents in 3T3-L1 cells treated with PnL extract and piperine were reduced to 34.5 and 44.9% of control cells, respectively (Figure 1D).

PnL Extract and Piperine Down-Regulate the mRNA Expression of Adipogenic Genes. The effect of PnL extract and piperine on lipid deposition prompted us to investigate their roles in gene expression upon adipogenesis of 3T3-L1 cells. Real-time RT-PCR revealed that both treatments greatly decrease the mRNA level of adipogenic transcription factors PPAR $\gamma$ , SREBP-1c, and C/EBP $\beta$  (Figure 2A). The down-regulation of PPAR $\gamma$  mRNA level by the treatments led us to determine the expression of PPAR $\gamma$  target genes, adipsin, aP2, and LPL. Indeed, both PnL extract and piperine reduced the mRNA level of these genes significantly compared to DMSO


control (Figure 2B). In all cases, the effect of piperine was more significant than the effect of the PnL extract.

**Piperine Alleviates the Ligand-Induced Transcriptional Activity of PPAR** $\gamma$ . PPAR $\gamma$  plays a pivotal role in adipocyte differentiation through regulation of adipogenic gene expression. To address the effect of piperine on the transcriptional activity of PPAR $\gamma$ , luciferase reporter gene assays were performed. HEK293 cells were cotransfected with PPRE-tk-luciferase reporter plasmid and PPAR $\gamma$  expression vector in the presence and absence of rosiglitazone, a specific ligand for PPAR $\gamma$ , and increasing concentrations of piperine. Subsequent luciferase assays indicated that piperine represses the transcriptional activity of PPAR $\gamma$  in both ligand-independent and -dependent manners (Figure 3). These results suggest that piperine may act as an antagonist of PPAR $\gamma$ , leading to inhibition of adipogenesis associated with PPAR $\gamma$  activation.

**Piperine Inhibits the Agonist-Induced PPAR**γ **Binding to Coactivator CBP.** It has been well documented that PPARγ activation is achieved by its ligand (or agonist)-induced PPARγ binding to coactivators such as CREB-binding protein (CBP). Thus, we postulated that the piperine-mediated PPARγ inactivation might result from the antagonistic activity of piperine on the ligand (rosiglitazone)-enhanced PPARγ binding to coactivator CBP. To confirm this hypothesis, the GST pull-down assay was employed using purified GST-CBP and His-PPARγ in the presence of rosiglitazone and piperine. As indicated in Figure 4A, rosiglitazone induced interaction between the N-terminal of CBP (amino acids 1–460) and the ligand-binding domain of PPARγ. This interaction was



**Figure 2.** Effect of PnL extract and piperine on the expression of adipogenic genes. 3T3-L1 cells were differentiated and treated with DMSO, PnL extract (50  $\mu$ g/mL), or piperine (50  $\mu$ M). Ten days following differentiation of 3T3-L1, the mRNA expression of PPAR $\gamma$ , SREBP-1c, C/EBP $\beta$ , adipsin, aP2, and LPL was monitored by qRT-PCR. The mRNA expression is normalized using GAPDH and shown by percentage of DMSO control. Bars represent mean values  $\pm$  SD of three independent experiments. \*, p < 0.05, and \*\*, p < 0.01, compared to DMSO control.



**Figure 3.** Piperine antagonizes PPARγ. HEK293 cells were transfected with vectors expressing PPARγ and PPRE-tk-luciferase reporter gene in the presence of rosiglitazone (Rosi, 1  $\mu$ M) and increasing concentrations of piperine as indicated. Luciferase activity was measured as described under Materials and Methods. Luciferase values were normalized to the  $\beta$ -galactosidase activity. Upper shows the structure of reporter gene. Bars represent mean values  $\pm$  SD of three independent experiments. \*, p < 0.05, and \*\*, p < 0.01, and a, p < 0.05, compared to DMSO control (lane 1).

gradually reduced by piperine in a dose-dependent manner, consistent with the result from the luciferase reporter assay. Gw9662, a known antagonist of PPAR $\gamma$ , was used for comparison (Figure 4B). Overall, our observations suggest that the piperine antagonism on PPAR $\gamma$  activity is attributed to its inhibitory effect on PPAR $\gamma$  binding to coactivator CBP.




Figure 4. Piperine disrupts rosiglitazone-induced PPAR $\gamma$  binding to CBP. GST pull-down assays were performed as described under Materials and Methods. Immobilized GST-CBP (amino acids 1–460 or 602–1095) fusion protein was incubated with increasing concentrations of piperine (A) or GW9662 (B) in the presence of 1 μM rosiglitazone and His-tagged PPAR $\gamma$  ligand-binding domain. Western blotting with anti-His antibody shows the effect of piperine on CBP recruitment to rosiglitazone-bound PPAR $\gamma$ . Input represents 20% of PPAR $\gamma$  used for binding assays.

Microarray Analysis and Validation. To explore the role of piperine in genome-wide regulation of adipogenesis, we performed microarray analysis using piperine- or PnL extracttreated 3T3-L1 cells and Agilent Mouse 44k 4plex. We identified 5733 genes differentially expressed, >2-fold, by piperine and 7053 genes by PnL extract (Figure 5A). Among those regulated genes, 3398 genes were coregulated by piperine and PnL extract. Further clustering analysis emphasized that PnL extract shares with piperine in controlling gene expression (Figure 5B). Both treatments significantly reduced mRNA expression levels of genes associated with adipocyte differentiation (Table 2). Consistent with our RT-qPCR data shown in Figure 2, the mRNA expression of PPARy, SREBP-1c, and C/EBP $\beta$ , adipsin, aP2, and LPL was significantly reduced. Other down-regulated genes were adiponectin, Lpin1, resistin, Scd1, and perilipin. In addition, genes associated with lipid biosynthesis and transport were greatly repressed, whereas lipolysis-associated genes were up-regulated by either treatment (Table 3). Some of the regulated genes newly identified from microarray analysis were validated by RT-qPCR: FATCD36, GLUT4, SCD1, and C/EBP $\beta$  (Figure 5C). Overall, our RTqPCR data were fairly consistent with microarray data, with little difference in magnitude. These genome-wide studies strongly suggest that piperine, as a critical component of PnL extract, plays a common role with PnL extract in regulating lipid metabolism.

# DISCUSSION

Obese condition increases the risk of fat-related disorders such as hyperglycemia, hyperlipidemia, hypercholesterolemia, and diabetes. There are many reports that natural compounds from herbal medicines or fruits have efficacies in disease-associated metabolic disorder and lipid metabolism. The fruit of P. nigrum has been used in oriental herbal medicine and worldwide as a spice in the form of black pepper. Piperine, one of the natural alkaloids, is a pungent ingredient of black pepper. In recent decades, various clinical efficacies of piperine have been reported. Focusing on its roles in lipid metabolism,




Figure 5. Gene expression profilings of PnL extract- and piperine-regulated adipogenesis and validation in 3T3-L1 cells. (A) Genes expressed differentially during adipogenesis by piperine or PnL ext are indicated in a Venn diagram. (B) Clustering analysis of 9388 genes was regulated by PnL extract and piperine. (C) Validation of gene expression selected in piperine- or PnL extract-regulated adipogenesis. Bars represent mean values  $\pm$  SD of three independent experiments. \*, p < 0.001, vs DMSO control.

Table 2. mRNA Expression Level of Genes Associated with Fat Cell Differentiation

	gene description	GenBank	fold change <sup>a</sup>	
name			Pip	PnL
Slc2a4	solute carrier family 2, member 4	NM_009204	0.073	0.049
Cebpb	CCAAT/enhancer binding protein (C/EBP), $\beta$	NM_009883	0.400	0.399
Cebpa	CCAAT/enhancer binding protein (C/EBP), $\alpha$	NM_007678	0.256	0.20
Srebf1	sterol regulatory element binding factor 1	NM_011480	0.527	0.44
Pparg	peroxisome proliferator activated receptor $\gamma$	NM_011146	0.178	0.26
Adipoq	adiponectin, C1Q and collagen domain containing	NM_009605	0.355	0.093
Adn	complement factor D (adipsin) (Cfd)	NM_013459	0.111	0.026
Lxra	nuclear receptor subfamily 1, group H, member 3	NM_013839	0.395	0.416
Ncor2	nuclear receptor corepressor 2	NM_011424	0.744	0.446
Fabp4	fatty acid binding protein 4, adipocyte (aP2)	NM_024406	0.216	0.440
Lpin1	lipin 1	NM_015763	0.123	0.219
Retn	resistin	NM_022984	0.054	0.028
Scd1	stearoyl-coenzyme A desaturase 1	NM_009127	0.090	0.05
Plin	perilipin	NM_175640	0.133	0.089

<sup>a</sup>Fold change indicates the fold change of mRNA expression level compared to untreated sample.

piperine inhibits the activity of acyl-CoA:cholesterol acyltransferase (ACAT), which is responsible for cholesteryl ester (CE) synthesis, thus leading to a reduction of lipid droplets in macrophages.<sup>37</sup> Other studies have suggested that piperine improves hyperglycemia, hyperlipidemia, and hypercholesterolemia by reducing the level of blood lipid, glucose, and cholesterol.<sup>27,28,38</sup> In our studies, we found that PnL extract and its constituent piperine reduce lipid storage in 3T3-L1 cells and block their differentiation into adipocytes.

Fully differentiated adipocytes increase the expression of adipocyte-specific genes. PnL extract and piperine reduced the

mRNA expression level of PPARγ, SREBP-1c, and C/EBPβ, key transcription factors associated with adipogenesis. The downstream target genes of these factors such as adipsin, aP2 (or Fabp4), and LPL were also down-regulated by PnL extract or piperine treatment in differentiated 3T3-L1 cells. As shown in our microarray data (Tables 2 and 3), the expression of other genes was also attenuated by both treatments: fatty acid translocase CD36, apolipoprotein C–II (Apoc2), and keratinocyte lipid-binding protein Fabp5 associated with fatty acid uptake and transport; Fasn, Scd1, Acsl1, Fads3, and Dgat1 involved in lipid synthesis; lipid droplet-associated protein

Table 3. mRNA Expression Level of Genes Associated with Lipid Metabolism

			fold change <sup>a</sup>					
name	gene description	GenBank	Pip	PnL				
Lipid Biosynthetic Process								
Fasn	fatty acid synthase	NM 007988	0.336	0.151				
Acsl1	acyl-CoA synthetase long- chain family member 1	NM_007981	0.152	0.070				
Acsl5	acyl-CoA synthetase long- chain family member 5	NM_027976	0.360	0.394				
Scd1	stearoyl-coenzyme A desaturase 1	NM_009127	0.090	0.054				
Fads3	fatty acid desaturase 3	NM_021890	0.439	0.687				
Cyp51	cytochrome P450, family 51	NM_020010	0.234	0.396				
Gpd1	glycerol-3-phosphate dehydrogenase 1 (soluble)	NM_010271	0.279	0.041				
Dgat2	diacylglycerol <i>O</i> - acyltransferase 2	NM_026384	0.144	0.248				
Dgat1	diacylglycerol <i>O-</i> acyltransferase 1	NM_010046	0.220	0.371				
Adipor1	adiponectin receptor 1	NM_028320	0.641	0.564				
Adipor2	adiponectin receptor 2	NM_197985	0.250	0.402				
	Lipid Catabolic Process							
Pld4	phospholipase D family, member 4	NM_178911	2.863	4.126				
Plcg1	phosphoinositide phospholipase C-γ-1 (ELP)	AF027185	3.446	3.825				
Clps	colipase, pancreatic	NM_025469	2.516	2.510				
Plcd1	phospholipase C, $\delta$ 1	NM_019676	2.717	2.399				
Acot7	acyl-CoA thioesterase 7	NM_133348	1.890	2.256				
Pla2g2d	phospholipase A2, group IID	NM_011109	2.606	2.178				
Hexa	hexosaminidase A	NM_010421	4.806	1.987				
Oc90	otoconin 90	NM_010953	1.933	1.928				
Cel	carboxyl ester lipase	Nm_009885	1.524	2.443				
	Uptake and Ti	ransport						
Slc37a4	solute carrier family 37, member 4	NM_008063	0.615	0.276				
Slc27a4	solute carrier family 27, member 4	NM_011989	0.353	0.620				
Slc22a4	solute carrier family 22, member 4	NM_019687	0.452	0.231				
Cd36	CD36 antigen (Fatcd36)	NM_007643	0.187	0.171				
Lpl	lipoprotein lipase	NM_008509	0.230	0.279				
Apoc2	apolipoprotein C-II	NM_009695	0.341	0.173				
Fabp4	fatty acid binding protein 4, adipocyte (ap2)	NM_024406	0.216	0.440				
Fabp5	Mal1 mrna for keratinocyte lipid-binding protein	X70100	0.105	0.143				
Slco2a1	prostaglandin transporter PGT mrna, complete cds	AF323958	8.903	9.450				

<sup>a</sup>Fold change indicates the fold change of mRNA expression level compared to untreated sample.

perilipin; PPAR $\gamma$  coactivator lipin 1; adiponectin and adiponectin receptors 1 and 2; adipokines-associated insulin sensitivity; GLUT4 involved in glucose uptake; and liver X receptor LXR $\alpha$ . In contrast, PnL extract and piperine increased the mRNA expression level of lipid catabolic process-associated genes, such as Pld4, Plcg1, colipase, plcd1, Acot7, and Cel (Table 3). Overall, these results suggest that PnL extract and piperine may inhibit adipogenesis of 3T3-L1 preadipocyte by down-regulating many genes associated with lipid accumulation in 3T3-L1 cells during differentiation and by up-regulating various genes associated with lipid catabolic process. In most

cases, PnL extract and piperine showed similar regulation patterns of gene expression. Given that piperine is a major component of PnL extract,<sup>20</sup> our data suggest that piperine is a functional ingredient of the PnL extract in playing a role in lipid metabolism. However, other components in PnL extract may account for differences in the magnitude of gene expression, lipid accumulation, and cellular toxicity.

It has been reported that PPARy plays a pivotal role in adipocyte differentiation through regulation of adipogenic gene expression.<sup>7,8</sup> As judged from the expression profiling of genes down-regulated by piperine, we found that the most genes are downstream targets of PPARy. These observations prompted us to investigate the molecular mechanism played by piperine. Our luciferase reporter assay indicated that piperine significantly inhibits the PPARy transcriptional activity. Subsequent binding assays displayed that piperine, like the known antagonist Gw9662, disrupts the ligand-dependent interaction between PPARy and CBP. It has been well documented that CBP functions as a PPARy coactivator by associating with agonistbound PPARy.31,32 In addition, CBP is indispensible for adipogenesis through the activation of PPARy.<sup>39</sup> Together with a positive role of PPARy in adipogenesis, we suggest that piperine may inhibit adipocyte differentiation of 3T3-L1 cells by its antagonistic activity against PPARy. Computer-based structural analysis implied that the ligand-binding domain of PPARy can accommodate piperine in its binding pocket (data not shown), further supporting that piperine may function as an antagonist of PPAR $\gamma$ , thus disrupting the interaction between agonist-bound PPARy and coactivator CBP. During our studies, we also found that piperine represses the transcriptional activity and expression level of LXR $\alpha$  (data not shown), another transcriptional factor that plays a pivotal role in inducing adipogenesis and biosynthesis of cholesterol and fatty acid through up-regulation of various genes such as SREBP-1c, Fasn, Scd1, and LPL. Interestingly, LXR $\alpha$  is not only up-regulated by PPAR $\gamma^{40-43}$  but also increases the expression of SERBP-1c<sup>44,45</sup> and PPAR $\gamma^{46}$  sharing several target genes such as Fasn, Scd1, LPL, and GLUT4. Therefore, these positive feedback loops may result in cascade regulation of lipid metabolism. Taken together, our findings suggest that piperine, a major component of black pepper, inhibits fat cell differentiation by down-regulating the transcriptional activity of PPAR $\gamma$  (and LXR $\alpha$ ) and suppressing the expression of PPAR $\gamma$ (and LXR $\alpha$ ), thus leading to its potential use in the treatment of obesity-related diseases.

#### AUTHOR INFORMATION

## **Corresponding Author**

\*(S.-J.U.) Phone: +82-2-3408-3641. Fax: +82-2-3408-4334. E-mail: umsj@sejong.ac.kr. (J.-C.J.) E-mail: jjcjh@paran.com.

#### **Funding**

This work was supported in part by Basic Science Research Program through NRF grant funded by the MEST (2012-0000655 to S.-J.U.) and in part by Health 21 R Project, Ministry of Health, Welfare, and Family Affairs (A090282 to S.-J.U.), Republic of Korea.

#### Notes

The authors declare no competing financial interest.

#### REFERENCES

(1) Campfield, L. A.; Smith, F. J.; Burn, P. Strategies and potential molecular targets for obesity treatment. *Science* **1998**, 280, 1383–1387.

- (2) Trujillo, M. E.; Scherer, P. E. Adipose tissue-derived factors: impact on health and disease. *Endocr. Rev.* **2006**, *27*, 762–778.
- (3) Gregoire, F. M.; Smas, C. M.; Sul, H. S. Understanding adipocyte differentiation. *Physiol. Rev.* **1998**, *78*, 783–809.
- (4) Rosen, E. D.; Walkey, C. J.; Puigserver, P.; Spiegelman, B. M. Transcriptional regulation of adipogenesis. *Genes Dev.* **2000**, *14*, 1293–1307.
- (5) Farmer, S. R. Transcriptional control of adipocyte formation. *Cell Metab.* **2006**, *4*, 263–273.
- (6) White, U. A.; Stephens, J. M. Transcriptional factors that promote formation of white adipose tissue. *Mol. Cell. Endocrinol.* **2010**, *318*, 10–14.
- (7) Tontonoz, P.; Spiegelman, B. M. Fat and beyond: the diverse biology of PPARy. Annu. Rev. Biochem. 2008, 77, 289-312.
- (8) Tontonoz, P.; Hu, E.; Spiegelman, B. M. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr. Opin. Genet. Dev. 1995, 5, 571–576.
- (9) Kageyama, H.; Hirano, T.; Okada, K.; Ebara, T.; Kageyama, A.; Murakami, T.; Shioda, S.; Adachi, M. Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-γ. Biochem. Biophys. Res. Commun. 2003, 305, 22–27.
- (10) Wang, L.; Shao, Y. Y.; Ballock, R. T. Peroxisome proliferator-activated receptor-γ promotes adipogenic changes in growth plate chondrocytes in vitro. *PPAR Res.* **2006**, *67297*.
- (11) Perera, R. J.; Marcusson, E. G.; Koo, S.; Kang, X.; Kim, Y.; White, N.; Dean, N. M. Identification of novel PPARy target genes in primary human adipocytes. *Gene* **2006**, *369*, 90–99.
- (12) Sears, D. D.; Hsiao, A.; Ofrecio, J. M.; Chapman, J.; He, W.; Olefsky, J. M. Selective modulation of promoter recruitment and transcriptional activity of PPARγ. *Biochem. Biophys. Res. Commun.* **2007**, 364, 515–521.
- (13) Nakachi, Y.; Yagi, K.; Nikaido, I.; Bono, H.; Tonouchi, M.; Schönbach, C.; Okazaki, Y. Identification of novel PPARγ target genes by integrated analysis of ChIP-on-chip and microarray expression data during adipocyte differentiation. *Biochem. Biophys. Res. Commun.* **2008**, 372, 362–366.
- (14) Nielsen, R.; Pedersen, T. A.; Hagenbeek, D.; Moulos, P.; Siersbaek, R.; Megens, E.; Denissov, S.; Børgesen, M.; Francoijs, K. J.; Mandrup, S.; Stunnenberg, H. G. Genome-wide profiling of PPARy: RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. *Genes Dev.* 2008, 22, 2953–2967.
- (15) Srinivasan, K. Black pepper and its pungent principle piperine: a review of diverse physiological effects. *Crit. Rev. Food Sci. Nutr.* **2007**, *47*, 735–748.
- (16) Rho, M. C.; Lee, S. W.; Park, H. R.; Choi, J. H.; Kang, J. Y.; Kim, K.; Lee, H. S.; Kim, Y. K. ACAT inhibition of alkamides identified in the fruits of *Piper nigrum. Phytochemistry* **2007**, *68*, 899–903.
- (17) Bajad, S.; Bedi, K. L.; Singla, A. K.; Johri, R. K. Antidiarrhoeal activity of piperine in mice. *Planta Med.* **2001**, *67*, 284–7.
- (18) Kaleem, M.; Sheema; Sarmad, H.; Bano, B. Protective effects of *Piper nigrum* and *Vinca rosea* in alloxan induced diabetic rats. *Indian J. Physiol. Pharmacol.* **2005**, *49*, 65–71.
- (19) Lee, S. W.; Rho, M. C.; Park, H. R.; Choi, J. H.; Kang, J. Y.; Lee, J. W.; Kim, K.; Lee, H. S.; Kim, Y. K. Inhibition of diacylglycerol acyltransferase by alkamides isolated from the fruits of *Piper longum* and *Piper nigrum*. *J. Agric. Food Chem.* **2006**, *54*, 9759–9763.
- (20) Szallasi, A. Piperine: researchers discover new flavor in an ancient spice. *Trends Pharmacol. Sci.* **2005**, *26*, 437–439.
- (21) Eun, J. S. A study on the mechanism of analgesic action of piperine. *Yakhak Hoeji* **1986**, *30*, 169–173.
- (22) Selvendiran, K.; Singh, J. P.; Krishnan, K. B.; Sakthisekaran, D. Cytoprotective effect of piperine against benzo[a]pyrene induced lung cancer with reference to lipid peroxidation and antioxidant system in Swiss albino mice. Fitoterapia 2003, 74, 109–115.
- (23) Vijayakumar, R. S.; Nalini, N. Efficacy of piperine, an alkaloidal constituent from *Piper nigrum* on erythrocyte antioxidant status in high

- fat diet and antithyroid drug induced hyperlipidemic rats. Cell. Biochem. Funct. 2006, 24, 491–498.
- (24) Bezerra, D. P.; Castro, F. O.; Alves, A. P.; Pessoa, C.; Moraes, M. O.; Silveira, E. R.; Lima, M. A.; Elmiro, F. J.; Costa-Lotufo, L. V. In vivo growth-inhibition of Sarcoma 180 by piplartine and piperine, two alkaloid amides from *Piper. Braz. J. Med. Biol. Res.* **2006**, 39, 801–807.
- (25) Bezerra, D. P.; de Castro, F. O.; Alves, A. P.; Pessoa, C.; de Moraes, M. O.; Silveira, E. R.; Lima, M. A.; Elmiro, F. J.; de Alencar, N. M.; Mesquita, R. O.; Lima, M. W.; Costa-Lotufo, L. V. In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine. *J. Appl. Toxicol.* **2008**, *28*, 156–163.
- (26) Mujumdar, A. M.; Dhuley, J. N.; Deshmukh, V. K.; Raman, P. H.; Naik, S. R. Anti-inflammatory activity of piperine. *Jpn. J. Med. Sci. Biol.* **1990**, 43, 95–100.
- (27) Jin, Z.; Borjihan, G.; Zhao, R.; Sun, Z.; Hammond, G. B.; Uryu, T. Antihyperlipidemic compounds from the fruit of *Piper longum L. Phytother. Res.* **2009**, 23, 1194–1196.
- (28) Panda, S.; Kar, A. Piperine lowers the serum concentrations of thyroid hormones, glucose and hepatic 5'D activity in adult male mice. *Horm. Metab. Res.* **2003**, *35*, 523–526.
- (29) Taqvi, S. I.; Shah, A. J.; Gilani, A. H. Blood pressure lowering and vasomodulator effects of piperine. *J. Cardiovasc. Pharmacol.* **2008**, 52, 452–458.
- (30) Cho, Y. S.; Kim, E. J.; Park, U. H.; Sin, H. S.; Um, S. J. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. *J. Biol. Chem.* **2006**, *281*, 17588–17598.
- (31) Mizukami, J.; Taniguchi, T. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR  $\gamma$  and CBP. *Biochem. Biophys. Res. Commun.* **1997**, 240, 61–64.
- (32) Klein, F. A.; Atkinson, R. A.; Potier, N.; Moras, D.; Cavarelli, J. Biochemical and NMR mapping of the interface between CREB-binding protein and ligand binding domains of nuclear receptor: beyond the LXXLL motif. *J. Biol. Chem.* **2005**, *280*, 5682–5692.
- (33) Lee, H. K.; Park, U. H.; Kim, E. J.; Um, S. J. MED25 is distinct from TRAP220/MED1 in cooperating with CBP for retinoid receptor activation. *EMBO J.* **2007**, *26*, 3545–3557.
- (34) Huang, T. H.; Kota, B. P.; Razmovski, V.; Roufogalis, B. D. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. *Basic Clin. Pharmacol. Toxicol.* **2005**, *96*, 3–14.
- (35) Yin, J.; Zhang, H.; Ye, J. Traditional chinese medicine in treatment of metabolic syndrome. *Endocr. Metab. Immune Disord. Drug Targets* **2008**, *8*, 99–111.
- (36) Samad, A.; Shams, M. S.; Ullah., Z.; Wais, M.; Nazish, I.; Sultana, Y.; Aqil, M. Status of herbal medicines in the treatment of diabetes: a review. *Curr. Diabetes Rev.* **2009**, *5*, 102–111.
- (37) Matsuda, D.; Ohte, S.; Ohshiro, T.; Jiang, W.; Rudel, L.; Hong, B.; Si, S.; Tomoda, H. Molecular target of piperine in the inhibition of lipid droplet accumulation in macrophages. *Biol. Pharm. Bull.* **2008**, *31*, 1063–1066.
- (38) Cho, S. Y.; Lee, S. H. Effect of black pepper on the composition of serum and liver in the rat. *Korean J. Food Nutr.* **1983**, *12*, 219–224.
- (39) Takahashi, N.; Kawada, T.; Yamamoto, T.; Goto, T.; Taimatsu, A.; Aoki, N.; Kawasaki, H.; Taira, K.; Yokoyama, K. K.; Kamei, Y.; Fushiki, T. Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor  $\gamma$ . *J. Biol. Chem.* **2002**, 277, 16906–16912.
- (40) Juvet, L. K.; Andresen, S. M.; Schuster, G. U.; Dalen, K. T.; Tobin, K. A.; Hollung, K.; Haugen, F.; Jacinto, S.; Ulven, S. M.; Bamberg, K.; Gustafsson, J. A.; Nebb, H. I. On the role of liver X receptors in lipid accumulation in adipocytes. *Mol. Endocrinol.* **2003**, *17*, 172–182.
- (41) Ulven, S. M.; Dalen, K. T.; Gustafsson, J. A.; Nebb, H. I. LXR is crucial in lipid metabolism. *Prostaglandins, Leukotrienes Essent. Fatty Acids* **2005**, 73, 59–63.

- (42) Nomiyama, T..; Bruemmer, D. Liver X receptors as therapeutic targets in metabolism and atherosclerosis. *Curr. Atheroscler. Rep.* **2008**, *10*, 88–95.
- (43) Chawla, A.; Boisvert, W. A.; Lee, C. H.; Laffitte, B. A.; Barak, Y.; Joseph, S. B.; Liao, D.; Nagy, L.; Edwards, P. A.; Curtiss, L. K; Evans, R. M; Tontonoz, P. A PPAR  $\gamma$ -LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. *Mol. Cell* **2001**, 7, 161–171.
- (44) Repa, J. J.; Liang, G.; Ou, J.; Bashmakov, Y.; Lobaccaro, J. M.; Shimomura, I.; Shan, B.; Brown, M. S.; Goldstein, J. L.; Mangelsdorf, D. J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR $\alpha$  and LXR $\beta$ . Genes Dev. **2000**, *14*, 2819–2830.
- (45) Yoshikawa, T.; Shimano, H.; Amemiya-Kudo, M.; Yahagi, N.; Hasty, A. H.; Matsuzaka, T.; Okazaki, H.; Tamura, Y.; Iizuka, Y.; Ohashi, K.; Osuga, J.; Harada, K.; Gotoda, T.; Kimura, S.; Ishibashi, S.; Yamada, N. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. *Mol. Cell. Biol.* **2001**, *21*, 2991–3000.
- (46) Seo, J. B.; Moon, H. M.; Kim, W. S.; Lee, Y. S.; Jeong, H. W.; Yoo, E. J.; Ham, J.; Kang, H.; Park, M. G.; Steffensen, K. R.; Stulnig, T. M.; Gustafsson, J. A.; Park, S. D.; Kim, J. B. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor  $\gamma$  expression. *Mol. Cell. Biol.* **2004**, *24*, 3430–3444.